一分钟看懂
这是一项关于淋巴瘤的早期 I 期研究，登记的药物或干预包括GI001，当前状态为招募中。登记地点显示中国云南省有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
GI001 · 早期 I 期
登记条件中文摘要
年龄范围：18岁至75岁
登记的基本范围为不限性别，年龄18岁至75岁；以下仅摘录8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- The 920th Hospital of Joint Logistics Support Force, PLA · 云南省
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- 1\. Age 18 to 75 years, inclusive.
- * 2\. Diagnosis of CD19-positive relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) or R/R B-cell acute lymphoblastic leukemia (B-ALL):
- * 2.1 CD19-positive R/R B-NHL meeting the following:
- * Histopathologic diagnosis of indolent NHL (iNHL), including but not limited to follicular lymphoma (FL) and marginal zone lymphoma (MZL), or small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL); or aggressive B-cell lymphoma, including but not limited to diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), transformed follicular lymphoma (TFL), and T-cell/histiocyte-rich large B-cell lymphoma (TCRBCL).
- * Refractory disease defined as: (a) best response of progressive disease (PD) to first-line standard therapy, or stable disease (SD) after at least 4 cycles of first-line therapy with SD duration not exceeding 6 months after the last treatment; or (b) no response to second-line or later therapy, including best response of PD to the most recent therapy, or SD after at least 2 cycles of the most recent therapy with SD duration not exceeding 6 months after the last treatment; or (c) disease progression within 12 months after autologous hematopoietic stem cell transplantation (ASCT) or biopsy-confirmed relapse, or no remission or relapse (SD or PD) after salvage therapy following ASCT.
- * Relapse defined as PD after achieving a response (partial response \[PR\] or complete response \[CR\]) to adequate prior therapy.
- * Note: participants must have received adequate prior therapy; participants with CD20-positive disease must have failed or relapsed after anti-CD20 monoclonal antibody therapy.
- * 2.2 CD19-positive R/R B-ALL meeting the following:
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07862010；登记信息更新于 2026-10-07；本站同步于 2026-10-08，中国中心当前名额未经人工确认。